Cargando…

Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee

Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasai, Shiho, Sato, Masato, Maehara, Miki, Toyoda, Eriko, Uchiyama, Ryoka, Takahashi, Takumi, Okada, Eri, Iwasaki, Yoshiko, Suzuki, Satoko, Watanabe, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324396/
https://www.ncbi.nlm.nih.gov/pubmed/32601400
http://dx.doi.org/10.1038/s41598-020-67099-y
_version_ 1783551932904767488
author Wasai, Shiho
Sato, Masato
Maehara, Miki
Toyoda, Eriko
Uchiyama, Ryoka
Takahashi, Takumi
Okada, Eri
Iwasaki, Yoshiko
Suzuki, Satoko
Watanabe, Masahiko
author_facet Wasai, Shiho
Sato, Masato
Maehara, Miki
Toyoda, Eriko
Uchiyama, Ryoka
Takahashi, Takumi
Okada, Eri
Iwasaki, Yoshiko
Suzuki, Satoko
Watanabe, Masahiko
author_sort Wasai, Shiho
collection PubMed
description Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two types of PRP purified using the Autologous Protein Solution (APS) kit (group Z; leucocyte-rich PRP) or the Cellaid Serum Collection Set P type (group J; leucocyte-poor [LP]-PRP). Differences in humoral factors between healthy subjects (n = 10) and OAK patients (n = 12; group Z = 6, group J = 6), and the relationship between humoral factors and clinical outcome scores were investigated. Both anti-inflammatory and inflammatory cytokines were highly enriched in APS. The concentrations of tumour necrosis factor (TNF)-α, platelet-derived growth factor, fibroblast growth factor, soluble TNF-receptor 2, soluble Fas and transforming growth factor-β1 were higher in group Z, while the total amounts were higher in group J. The concentration of interleukin-1 receptor antagonist was positively correlated with the magnitude of change in the clinical outcome score and may contribute to improving knee-joint function. This is the first description of the humoral factors in APS and LP-PRP prepared from healthy subjects or OAK patients of Asian descent.
format Online
Article
Text
id pubmed-7324396
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-73243962020-06-30 Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee Wasai, Shiho Sato, Masato Maehara, Miki Toyoda, Eriko Uchiyama, Ryoka Takahashi, Takumi Okada, Eri Iwasaki, Yoshiko Suzuki, Satoko Watanabe, Masahiko Sci Rep Article Recently, platelet-rich plasma (PRP) has received attention as a treatment for patients with osteoarthritis of the knee (OAK), a chronic degenerative disease, to bridge the gap between conservative and surgical treatments. Here, we investigated the differences in the humoral factors present in two types of PRP purified using the Autologous Protein Solution (APS) kit (group Z; leucocyte-rich PRP) or the Cellaid Serum Collection Set P type (group J; leucocyte-poor [LP]-PRP). Differences in humoral factors between healthy subjects (n = 10) and OAK patients (n = 12; group Z = 6, group J = 6), and the relationship between humoral factors and clinical outcome scores were investigated. Both anti-inflammatory and inflammatory cytokines were highly enriched in APS. The concentrations of tumour necrosis factor (TNF)-α, platelet-derived growth factor, fibroblast growth factor, soluble TNF-receptor 2, soluble Fas and transforming growth factor-β1 were higher in group Z, while the total amounts were higher in group J. The concentration of interleukin-1 receptor antagonist was positively correlated with the magnitude of change in the clinical outcome score and may contribute to improving knee-joint function. This is the first description of the humoral factors in APS and LP-PRP prepared from healthy subjects or OAK patients of Asian descent. Nature Publishing Group UK 2020-06-29 /pmc/articles/PMC7324396/ /pubmed/32601400 http://dx.doi.org/10.1038/s41598-020-67099-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wasai, Shiho
Sato, Masato
Maehara, Miki
Toyoda, Eriko
Uchiyama, Ryoka
Takahashi, Takumi
Okada, Eri
Iwasaki, Yoshiko
Suzuki, Satoko
Watanabe, Masahiko
Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title_full Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title_fullStr Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title_full_unstemmed Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title_short Characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
title_sort characteristics of autologous protein solution and leucocyte-poor platelet-rich plasma for the treatment of osteoarthritis of the knee
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324396/
https://www.ncbi.nlm.nih.gov/pubmed/32601400
http://dx.doi.org/10.1038/s41598-020-67099-y
work_keys_str_mv AT wasaishiho characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT satomasato characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT maeharamiki characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT toyodaeriko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT uchiyamaryoka characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT takahashitakumi characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT okadaeri characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT iwasakiyoshiko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT suzukisatoko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee
AT watanabemasahiko characteristicsofautologousproteinsolutionandleucocytepoorplateletrichplasmaforthetreatmentofosteoarthritisoftheknee